Atomizable anti-fatigue drug composition

Abstract

The present invention provides an anti-fatigue pharmaceutical composition that can be atomized. The anti-fatigue pharmaceutical composition that can be atomized includes: active extracts and solvents, and the active extracts include at least one of Herba Lycopodii extracts, Radix Astragali extracts, Radix Polygonati extracts, Radix Ginseng extracts, Radix Panax Ginseng extracts, Radix Codonopsis extracts, Herba Cistanches extracts, Cordyceps sinensis extracts, Fructus Corni extracts, Folium Eucommiae extracts, Radix Angelicae Sinensis extracts, Radix Glycyrrhizae extracts, Pericarpium Citri Reticulatae extracts, Rhizoma Zingiberis extracts, Cortex Cinnamomi extracts, Polygonatum odoratum extracts and Radix Puerariae extracts. Therefore, the anti-fatigue pharmaceutical composition of the present invention can be atomized, which can greatly improve the absorption of the drug by the human body, and the absorption is fast, the effect is fast, and the dosage is small, thereby achieving better anti-fatigue effect, and it is also convenient and portable; moreover, the active extracts are all natural herbal extracts, which have little side effects on the human body and good efficacy.

Description

Technical Field

[0001] The present invention relates to the technical field of compositions, and in particular to an atomizable anti-fatigue drug composition. Background Art

[0002] The pace of social life is getting faster and faster. High-intensity work and study can easily cause fatigue and even fatigue syndrome. Fatigue cannot be effectively relieved, which will seriously affect physical health and lead to a series of diseases. Nebulization is a fast delivery method that can deliver substances with anti-fatigue effects to the human body, but there are currently no nebulization products that can play an anti-fatigue role. Summary of the invention

[0003] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, one object of the present invention is to provide an atomizable anti-fatigue pharmaceutical composition.

[0004] In one aspect of the present invention, the present invention provides an anti-fatigue pharmaceutical composition that can be atomized. According to an embodiment of the present invention, it includes: an active extract and a solvent, and the active extract includes at least one of a Radix Codonopsis pilosulae extract, a Radix Astragali extract, a Radix Polygonati sibiricum extract, a Radix Ginseng extract, a Radix Panax Ginseng extract, a Radix Codonopsis pilosulae extract, a Herba Cistanches deserticola extract, a Cordyceps sinensis extract, a Fructus Corni extract, a Herba Eucommiae extract, a Radix Angelicae Sinensis extract, a Radix Glycyrrhizae extract, a Pericarpium Citri Reticulatae extract, a Radix Gingerae extract, a Cortex Cinnamomi extract, a Polygonatum odoratum extract, and a Radix Puerariae extract. Thus, the anti-fatigue pharmaceutical composition of the present invention can be atomized, and can be taken into the human body by atomization inhalation, which can greatly improve the absorption of the drug by the human body, and has fast absorption, fast onset of effect, and small dosage, thereby achieving better anti-fatigue effect, and is also convenient and portable; moreover, the active extracts are all natural herbal extracts, which have little side effects on the human body and good efficacy.

[0005] According to an embodiment of the present invention, based on the total weight of the anti-fatigue pharmaceutical composition, it includes: 0.1% to 5% of the active extract; 0.01% to 3% of a sweetener; 0.1% to 5% of a cooling agent; 0.01% to 5% of an essence; and the remainder of a solvent.

[0006] According to an embodiment of the present invention, the cooling agent is selected from at least one of menthol, menthone, isomenthone, l-menthyl lactate, WS-23, WS-3, WS-5, WS-12, neomenthol, isopulegol, menthyl acetate, isopulegyl acetate, menthyl isovalerate and pulegone; the sweetener is selected from at least one of sucralose, neotame, sodium cyclamate, acesulfame potassium, aspartame, steviol glycoside neohesperidin dihydrochalcone and hesperidin dihydrochalcone; the fragrance is selected from limonene , benzyl alcohol, ethyl butyrate, vanillin, citronellal, isopentanol, ethyl maltol, linalool, isobutyl acetate, isopentanol, benzyl benzoate, leaf alcohol, ethyl propionate, citral, γ-decalactone, decanal, ethyl acetate, ethyl 2-methylbutyrate, 2-methylbutyl acetate, 2-methylbutyraldehyde, myrcene, ethyl caproate, peach aldehyde, ethyl isovalerate, leaf alcohol acetate, acetic acid, benzaldehyde and 2-methylbutyric acid, and the solvent is selected from at least one of propylene glycol, glycerol, water and ethanol.

[0007] According to an embodiment of the present invention, the Herba Lysimachiae extract is prepared by the following method: weighing 1 kg of Herba Lysimachiae tablets, ultrasonically extracting with 75-95% ethanol in an amount 8-15 times the mass of the Herba Lysimachiae tablets for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75-95% ethanol in an amount 3-8 times the mass of the Herba Lysimachiae tablets to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving with a small amount of 0-30% ethanol, passing through a macroporous resin, eluting with the 75-95% ethanol, and collecting the eluate; after the eluate is concentrated under reduced pressure, freeze-dried or vacuum-dried to powder, the Herba Lysimachiae extract is obtained.

[0008] According to an embodiment of the present invention, the kudzu root extract is prepared by the following method: weighing 1 kg of kudzu root block, ultrasonically extracting with 75-95% ethanol in an amount of 8-15 times the mass of the kudzu root block for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75-95% ethanol in an amount of 3-8 times the mass of the kudzu root block to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant to dryness, then dissolving with a small amount of 0-30% ethanol, passing through a macroporous resin, eluting with 20-40% ethanol and the 75-95% ethanol in turn, collecting the eluates respectively, and concentrating the eluate eluted with the 75-95% ethanol under reduced pressure and then freeze-drying or vacuum drying to powder, so as to obtain the kudzu root extract.

[0009] According to an embodiment of the present invention, the polygonatum extract is prepared by the following method: weighing 1 kg of polygonatum slices, ultrasonically extracting with 65-85% ethanol in an amount 8-15 times the mass of the polygonatum slices for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 65-85% ethanol in an amount 3-8 times the mass of the polygonatum slices to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving with a small amount of 0-30% ethanol water, passing through a macroporous resin, eluting with 70-90% ethanol, and collecting the eluate; after the eluate is concentrated under reduced pressure, it is freeze-dried or vacuum-dried to powder to obtain the polygonatum extract.

[0010] According to an embodiment of the present invention, the polygonatum extract, the ginseng extract, the American ginseng extract, the codonopsis extract, the cistanche extract, and the cornus extract are prepared by the following methods: weighing 1 kg of active raw materials, the active raw materials are polygonatum slices, ginseng, American ginseng, codonopsis, cistanche or cornus, using 8-15 times the mass of the active raw materials and 65-85% ethanol for ultrasonic extraction for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 3-8 times the mass of the active raw materials to the filter residue, ultrasonic extraction for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 500-800g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the active extract.

[0011] According to an embodiment of the present invention, the licorice extract, the astragalus extract, the eucommia leaf extract, the angelica extract, the dried ginger extract, and the cinnamon extract are respectively prepared by the following methods: weighing 1 kg of an active raw material, wherein the active raw material is a licorice tablet, an astragalus tablet, an eucommia leaf, angelica, dried ginger or cinnamon, using 50-70% ethanol in an amount 8-15 times the mass of the active raw material for ultrasonic extraction for 30-120 min, filtering to obtain a primary filtrate and a filter residue, adding 50-70% ethanol in an amount 3-8 times the mass of the active raw material to the filter residue, ultrasonic extraction for 10-60 min, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500 g to obtain a concentrated solution; then adding 3-5 kg ​​of an aqueous solution of 95% ethanol to the concentrated solution while stirring, and precipitating with alcohol for at least 10 hours to obtain a supernatant; concentrating the supernatant under reduced pressure until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the active extract.

[0012] According to an embodiment of the present invention, the tangerine peel extract is prepared by the following method: weighing 1 kg of tangerine peel, ultrasonically extracting with 40-60% ethanol in an amount of 8-15 times the mass of the tangerine peel for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding the 40-60% ethanol in an amount of 3-8 times the mass of the tangerine peel to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 500-800g to obtain a concentrated solution; then adding 3-5 kg ​​of an aqueous solution of 95% ethanol to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking a supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the tangerine peel extract.

[0013] According to an embodiment of the present invention, the Cordyceps sinensis extract is prepared by the following method: weighing 1 kg of Cordyceps sinensis, ultrasonically extracting with 65-85% ethanol in an amount 20-40 times the mass of the Cordyceps sinensis for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 65-85% ethanol in an amount 10-20 times the mass of the Cordyceps sinensis to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 500-800g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the Cordyceps sinensis extract. DETAILED DESCRIPTION

[0014] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0015] The present invention is described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and do not limit the present invention in any way.

[0016] In one aspect of the present invention, the present invention provides an anti-fatigue pharmaceutical composition that can be atomized. According to an embodiment of the present invention, it includes: active extracts and solvents, and the active extracts include at least one of Herba Lycopodii extracts, Radix Astragali extracts, Radix Polygonati extracts, Radix Ginseng extracts, Radix Panax Ginseng extracts, Radix Codonopsis extracts, Herba Cistanches extracts, Cordyceps sinensis extracts, Fructus Corni extracts, Folium Eucommiae extracts, Radix Angelicae Sinensis extracts, Radix Glycyrrhizae extracts, Pericarpium Citri Reticulatae extracts, Rhizoma Zingiberis extracts, Cortex Cinnamomi extracts, Radix Polygonati Odorati extracts and Radix Puerariae extracts. Thus, the anti-fatigue pharmaceutical composition of the present invention can be atomized, and can be taken into the human body by atomization inhalation, which can greatly improve the absorption of the drug by the human body, and has fast absorption, fast onset of effect, and small dosage, thereby achieving better anti-fatigue effect, and is convenient and portable; moreover, the active extracts are all natural herbal extracts, with small side effects on the human body and good efficacy.

[0017] According to an embodiment of the present invention, based on the total weight of the anti-fatigue pharmaceutical composition, the anti-fatigue pharmaceutical composition comprises: 0.1% to 5% (e.g., 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%) of the active extract; 0.01% to 3% (e.g., 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%) of a sweetener ; 0.1% to 5% (e.g. 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%) of cooling agent; 0.01% to 5% (e.g. 0.01%, 0.05%, 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%) of flavor; and the remainder of solvent. Therefore, the anti-fatigue pharmaceutical composition with the above component ratio has a good atomization effect and a better anti-fatigue effect; relative to the above range of the present application, if the content of the active extract component is low, the anti-fatigue effect is relatively poor; if the content of the active extract component is high, the atomization effect of the composition will be relatively poor, and it will easily become mushy during atomization, resulting in side reactions and the production of harmful substances to humans or mice.

[0018] According to an embodiment of the present invention, the cooling agent is selected from at least one of menthol, menthone, isomenthone, l-menthyl lactate, WS-23, WS-3, WS-5, WS-12, neomenthol, isopulegol, menthyl acetate, isopulegyl acetate, menthyl isovalerate and pulegone; the sweetener is selected from at least one of sucralose, neotame, sodium cyclamate, acesulfame potassium, aspartame, steviol glycoside neohesperidin dihydrochalcone and hesperidin dihydrochalcone; the fragrance is selected from at least one of limonene, benzene At least one of methanol, ethyl butyrate, vanillin, citronellal, isopentanol, ethyl maltol, linalool, isobutyl acetate, isopentanol, benzyl benzoate, leaf alcohol, ethyl propionate, citral, γ-decalactone, decanal, ethyl acetate, ethyl 2-methylbutyrate, 2-methylbutyl acetate, 2-methylbutyraldehyde, myrcene, ethyl caproate, peach aldehyde, ethyl isovalerate, leaf alcohol acetate, acetic acid, benzaldehyde and 2-methylbutyric acid, and the solvent is selected from at least one of propylene glycol, glycerol, water and ethanol. Therefore, the above components are widely available and easy to obtain, and the compatibility between different reagents is high, and the mixing is relatively uniform, which ensures that the anti-fatigue pharmaceutical composition is easier to atomize and has a better anti-fatigue effect.

[0019] According to an embodiment of the present invention, the Herba Lysimachiae extract is prepared by the following method: weighing 1 kg of Herba Lysimachiae tablets, ultrasonically extracting with 75-95% ethanol in an amount 8-15 times the mass of the Herba Lysimachiae tablets for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75-95% ethanol in an amount 3-8 times the mass of the Herba Lysimachiae tablets to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500 g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving with a small amount of 0-30% ethanol, passing through a macroporous resin, eluting with 75-95% ethanol, and collecting the eluate; after the eluate is concentrated under reduced pressure, freeze-dried or vacuum-dried to powder, the Herba Lysimachiae extract is obtained.

[0020] According to an embodiment of the present invention, the kudzu root extract is prepared by the following method: weighing 1 kg of kudzu root block, ultrasonically extracting with 75-95% ethanol in an amount of 8-15 times the mass of the kudzu root block for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75-95% ethanol in an amount of 3-8 times the mass of the kudzu root block to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant to dryness, then dissolving with a small amount of 0-30% ethanol, passing through a macroporous resin, eluting with 20-40% ethanol and 75-95% ethanol in sequence, collecting the eluates respectively, and concentrating the eluate eluted with 75-95% ethanol under reduced pressure and then freeze-drying or vacuum drying to powder, so as to obtain the kudzu root extract.

[0021] According to an embodiment of the present invention, the polygonatum extract is prepared by the following method: weighing 1 kg of polygonatum slices, ultrasonically extracting with 65-85% ethanol in an amount 8-15 times the mass of the polygonatum slices for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 65-85% ethanol in an amount 3-8 times the mass of the polygonatum slices to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving it with a small amount of 0-30% ethanol water, passing through a macroporous resin, eluting with 70-90% ethanol, and collecting the eluate; after the eluate is concentrated under reduced pressure, it is freeze-dried or vacuum-dried to powder to obtain the polygonatum extract.

[0022] According to an embodiment of the present invention, the extract of polygonatum, ginseng, American ginseng, Codonopsis, Cistanche and Cornus officinalis are prepared by the following methods: 1 kg of active raw materials are weighed, the active raw materials are polygonatum slices, ginseng, American ginseng, Codonopsis, Cistanche or Cornus officinalis, and 8-15 times the mass of the active raw materials are ultrasonically extracted with 65-85% ethanol for 30-120 min, filtered to obtain a primary filtrate and a filter residue, 3-8 times the mass of the active raw materials are added to the filter residue with 65-85% ethanol, ultrasonically extracted for 10-60 min, filtered to obtain a secondary filtrate, the primary filtrate and the secondary filtrate are combined, and concentrated under reduced pressure to 500-800 g to obtain a concentrated solution; then 3-5 kg ​​of 95% ethanol aqueous solution is added to the concentrated solution while stirring, and the alcohol precipitation is carried out for at least 10 hours to obtain the supernatant; the supernatant is concentrated under reduced pressure until there is no alcohol taste, and then powdered by freeze drying or vacuum drying to obtain an active extract.

[0023] According to an embodiment of the present invention, licorice extract, astragalus extract, eucommia leaf extract, angelica extract, dried ginger extract, and cinnamon extract are prepared by the following methods: weighing 1 kg of active raw materials, the active raw materials are licorice tablets, astragalus tablets, eucommia leaves, angelica, dried ginger or cinnamon, using 50-70% ethanol in an amount 8-15 times the mass of the active raw materials for ultrasonic extraction for 30-120 min, filtering to obtain a primary filtrate and a filter residue, adding 50-70% ethanol in an amount 3-8 times the mass of the active raw materials to the filter residue, ultrasonic extraction for 10-60 min, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 300-500 g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking the supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain an active extract.

[0024] According to an embodiment of the present invention, the tangerine peel extract is prepared by the following method: weighing 1 kg of tangerine peel, ultrasonically extracting with 40-60% ethanol in an amount of 8-15 times the mass of the tangerine peel for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 40-60% ethanol in an amount of 3-8 times the mass of the tangerine peel to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 500-800g to obtain a concentrated solution; then adding 3-5 kg ​​of an aqueous solution of 95% ethanol to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking a supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the tangerine peel extract.

[0025] According to an embodiment of the present invention, the Cordyceps sinensis extract is prepared by the following method: weighing 1 kg of Cordyceps sinensis, ultrasonically extracting with 65-85% ethanol in an amount 20-40 times the mass of Cordyceps sinensis for 30-120 minutes, filtering to obtain a primary filtrate and a filter residue, adding 65-85% ethanol in an amount 10-20 times the mass of Cordyceps sinensis to the filter residue, ultrasonically extracting for 10-60 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 500-800g to obtain a concentrated solution; then adding 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, alcohol precipitation for at least 10 hours, and taking the supernatant; decompressing and concentrating the supernatant until there is no alcohol taste, and then powdering by freeze drying or vacuum drying to obtain the Cordyceps sinensis extract.

[0026] According to the embodiments of the present invention, the method for preparing the active extract is simple and easy to implement, and the obtained active extract has a better yield and higher purity, and it is easier to achieve the atomization of the drug.

[0027] According to an embodiment of the present invention, the atomizable anti-fatigue pharmaceutical composition of the present invention can be atomized and used by an electronic atomizer.

[0028] Example

[0029] Example 1

[0030] The components and mass contents of the anti-fatigue drug composition (active extract content is 0.10%) are:

[0031]

[0032] Example 2

[0033] The components and mass contents of the anti-fatigue drug composition (active extract content is 0.30%) are:

[0034]

[0035] Example 3

[0036] The components and mass contents of the anti-fatigue drug composition (active extract content is 0.50%) are:

[0037]

[0038]

[0039] Example 4

[0040] The components and mass contents of the anti-fatigue drug composition (active extract content is 0.80%) are:

[0041]

[0042] Example 5

[0043] The components and mass contents of the anti-fatigue drug composition (active extract content is 1.00%) are:

[0044]

[0045] Example 6

[0046] The components and mass contents of the anti-fatigue drug composition (active extract content is 2.00%) are:

[0047]

[0048]

[0049] Example 7

[0050] The components and mass contents of the anti-fatigue drug composition (active extract content is 3.00%) are:

[0051]

[0052] Example 8

[0053] The components and mass contents of the anti-fatigue drug composition (active extract content is 4.00%) are:

[0054]

[0055]

[0056] Example 9

[0057] The components and mass contents of the anti-fatigue drug composition (active extract content is 5.00%) are:

[0058]

[0059] Example 10

[0060] The components and mass contents of the anti-fatigue drug composition (active extract content is 6.00%) are:

[0061]

[0062] The active extracts used in Examples 1 to 10 above were prepared by the following method:

[0063] The extract of Herba Lysimachiae is prepared by the following method: weighing 1kg of Herba Lysimachiae tablets, ultrasonically extracting with 90% ethanol in an amount 10 times the mass of the Herba Lysimachiae tablets for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 90% ethanol in an amount 5 times the mass of the Herba Lysimachiae tablets to the filter residue, ultrasonically extracting for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 400g to obtain a concentrated solution; then adding 4kg of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking a supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving with a small amount of 15% ethanol, passing through a macroporous resin, eluting with 90% ethanol, and collecting the eluate; and powdering the eluate by freeze drying or vacuum drying after concentrating the eluate under reduced pressure to obtain the Herba Lysimachiae extract.

[0064] The kudzu root extract is prepared by the following method: weighing 1 kg of kudzu root block, using 90% ethanol in an amount of 10 times the mass of the kudzu root block for ultrasonic extraction for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding the 90% ethanol in an amount of 5 times the mass of the kudzu root block to the filter residue, ultrasonic extraction for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 400 g to obtain a concentrated solution; then adding 4 kg of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking a supernatant; concentrating the supernatant to dryness, then dissolving it with a small amount of water or 30% ethanol, passing it through a macroporous resin, eluting it with 30% ethanol and 90% ethanol in sequence, collecting the eluates respectively, and concentrating the eluate eluted with 90% ethanol under reduced pressure and then preparing powder by freeze drying or vacuum drying to obtain the kudzu root extract.

[0065] The polygonatum sibiricum extract is prepared by the following method: weighing 1kg of polygonatum sibiricum slices, ultrasonically extracting with 75% ethanol in an amount 10 times the mass of the polygonatum sibiricum slices for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75% ethanol in an amount 5 times the mass of the polygonatum sibiricum slices to the filter residue, ultrasonically extracting for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 400g to obtain a concentrated solution; then adding 4kg of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitating with alcohol for at least 10 hours, and taking a supernatant; concentrating the supernatant under reduced pressure to dryness, then dissolving with a small amount of 15% ethanol water, passing through a macroporous resin, eluting with 80% ethanol, and collecting the eluate; and powdering the eluate by freeze drying or vacuum drying after concentrating the eluate under reduced pressure to obtain the polygonatum sibiricum extract.

[0066] The extract of polygonatum odoratum, the extract of ginseng, the extract of American ginseng, the extract of codonopsis pilosula, the extract of cistanche deserticola and the extract of cornus officinalis are prepared by the following methods: 1 kg of active raw materials are weighed, the active raw materials are polygonatum odoratum slices, ginseng, American ginseng, codonopsis pilosula, cistanche deserticola or cornus officinalis, 75% ethanol in an amount of 10 times the mass of the active raw materials is ultrasonically extracted for 60 minutes, and a primary filtrate and a filter residue are obtained by filtering, 75% ethanol in an amount of 5 times the mass of the active raw materials is added to the filter residue, ultrasonic extraction is performed for 30 minutes, and a secondary filtrate is obtained by filtering, the primary filtrate and the secondary filtrate are combined, and the concentrated solution is reduced in pressure to 700 g, and then a 4 kg 95% ethanol aqueous solution is added to the concentrated solution while stirring, and the alcohol precipitation is carried out for at least 10 hours, and the supernatant is taken; the supernatant is concentrated under reduced pressure until there is no alcohol taste, and then powdered by freeze drying or vacuum drying to obtain the active extract.

[0067] The licorice extract, astragalus extract, eucommia leaf extract, angelica extract, dried ginger extract and cinnamon extract are respectively prepared by the following methods: weighing 1 kg of active raw materials, which are licorice slices, astragalus slices, eucommia leaf leaves, angelica, dried ginger or cinnamon, using 60% ethanol in an amount 10 times the mass of the active raw materials for ultrasonic extraction for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 60% ethanol in an amount 5 times the mass of the active raw materials to the filter residue, ultrasonic extraction for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 400 g to obtain a concentrated solution; then adding 4 kg of 95% ethanol aqueous solution to the concentrated solution while stirring, and precipitating with alcohol for at least 10 hours to obtain a supernatant; concentrating the supernatant under reduced pressure until there is no alcohol taste, and then preparing powder by freeze drying or vacuum drying to obtain the active extract.

[0068] The tangerine peel extract is prepared by the following method: weighing 1 kg of tangerine peel, ultrasonically extracting with 50% ethanol in an amount 10 times the mass of the tangerine peel for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 50% ethanol in an amount 5 times the mass of the tangerine peel to the filter residue, ultrasonically extracting for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 700 g to obtain a concentrated solution; then adding 4 kg of a 95% ethanol aqueous solution to the concentrated solution while stirring, performing alcohol precipitation for at least 10 hours, and taking a supernatant; and decompressing and concentrating the supernatant until there is no alcohol taste, and then preparing powder by freeze drying or vacuum drying to obtain the tangerine peel extract.

[0069] The cordyceps sinensis extract is prepared by the following method: weighing 1 kg of cordyceps sinensis, ultrasonically extracting with 75% ethanol in an amount 30 times the mass of the cordyceps sinensis for 60 minutes, filtering to obtain a primary filtrate and a filter residue, adding 75% ethanol in an amount 15 times the mass of the cordyceps sinensis to the filter residue, ultrasonically extracting for 30 minutes, filtering to obtain a secondary filtrate, combining the primary filtrate and the secondary filtrate, and concentrating under reduced pressure to 700 g to obtain a concentrated solution; then adding 4 kg of a 95% ethanol aqueous solution to the concentrated solution while stirring, and performing alcohol precipitation for at least 10 hours to obtain a supernatant; and concentrating the supernatant under reduced pressure to remove alcohol taste, and then preparing powder by freeze drying or vacuum drying to obtain the cordyceps sinensis extract.

[0070] The anti-fatigue pharmaceutical compositions in Examples 1 to 10 were tested as follows:

[0071] 1. Taste test

[0072] Statistical method: 36 reviewers were selected to conduct evaluation tests on the electronic atomized liquid of the anti-fatigue pharmaceutical composition in the above Examples 1-10 through an electronic atomizer, and their taste was evaluated after the evaluation test, wherein the evaluation criteria were based on a total score of 5 points, and the specific scoring criteria are shown in Table 1. The test results of Examples 1 to 10 are shown in Table 2. The better the taste, the higher the score. The evaluation score ≥ 3 points is qualified.

[0073] Table 1

[0074]

[0075]

[0076] Table 2

[0077] sample Rating value Example 1 3.5 Example 2 4.7 Example 3 4.5 Example 4 4.6 Example 5 3.8 Example 6 4.4 Example 7 4.2 Example 8 4.0 Example 9 4.1 Example 10 2.8

[0078] 2. Suction

[0079] 200 cartridges were smoked by humans and machines, with humans smoking 10 puffs and machines smoking 30 puffs in a cycle, for a total of 200 puffs. The machines smoked according to the CORESTA smoking method, with a smoking time of 3.0s±0.1s; an interval of 30.0s±0.5s; a smoke volume of 55.0mL±0.3mL per puff, and humans smoked freely. The burnt smell of the cartridges was evaluated and the percentage was calculated. The results are shown in Table 3. The cartridges with a burnt smell of ≤1% were selected as qualified.

[0080] Table 3

[0081]

[0082]

[0083] 3. TPM value test

[0084] Smoking method: According to the CORESTA smoking method, the smoking time is 3.0s±0.1s; the interval time is 30.0s±0.5s; the smoke volume per puff is 55.0mL±0.3mL, and the total number of puffs is 200.

[0085] Test method: Calculate the average TPM value per puff between 25 and 175 puffs. See Table 4 for the results.

[0086] The TPM value ≥5.5mg / oral is considered qualified.

[0087] Table 4

[0088] Sample name TPM value (mg / mouth) Example 1 6.9 Example 2 6.7 Example 3 6.6 Example 4 6.6 Example 5 6.4 Example 6 6.2 Example 7 6.1 Example 8 5.8 Example 9 5.6 Example 10 5.1

[0089] 4. Efficacy experiment

[0090] 4-1 Test samples

[0091] Example 3, Example 5, Example 7, Example 9, Example 10

[0092] 4-2 Evaluation Animals

[0093] 120 healthy SPF C57BL / 6J mice, 6-8 weeks old, weighing (20±2) g, male.

[0094] 4-3 Evaluation Method

[0095] 72 C57BL / 6J male mice were randomly divided into 6 groups, 12 mice in each group, namely the control group, Example 3 group, Example 5 group, Example 7 group, Example 9 group, and Example 10 group. The drugs were administered by oral and nasal inhalation using a single-concentration oral and nasal exposure system combined with an electronic cigarette atomizer, 1 h / d per day, for 30 days. During the experiment, the changes in body weight and food intake of the mice were continuously observed, and the exhaustion time of the mice's weight-bearing swimming, as well as the biochemical indicators of glycogen (Gly) in liver homogenate, lactic acid (LD) in serum, and blood urea nitrogen (BUN) were measured. The control group was not given any drugs.

[0096] A. Load swimming test

[0097] Before the experiment, mice were trained to swim once. During the experiment, 5% of the body weight of lead was tied to the tail of the mouse and placed in a swimming box (50cm×50cm×40cm) with a water temperature of 25°C and a water depth of 35cm to ensure that the mice had sufficient swimming range to avoid collisions with each other. If any of them stopped to swim with their waist bent or rested in suspension during swimming, they were stimulated to swim with a glass rod to prevent laziness. A stopwatch was used to record the time from the start of swimming to exhaustion (if they sank underwater for more than 8s and could not float to the surface, it was considered exhaustion) as the swimming time of the mouse.

[0098] Data processing and result determination: Perform a significance analysis on the data. If the weighted swimming time of the test sample group is significantly longer than that of the control group, and the difference is significant (p≤0.05), the experimental result can be determined to be positive, otherwise it is negative.

[0099] B. Liver glycogen determination (anthrone method) experiment

[0100] One hour after the last administration of the drug to the mice, the mice were placed in water at 25°C to swim without load for 90 minutes, rested for 30 minutes, and their eyeballs were removed for blood collection. Then, the mice were killed immediately and their livers were removed. Fresh liver samples were rinsed with physiological saline, dried with filter paper, and weighed (sample weight should be ≤100 mg, not >100 mg).

[0101] Preparation of standard application solution: 1 mg / ml standard stock solution: double distilled water = 1:99, prepare before use.

[0102] Hydrolysis: add the sample weight (mg) to the volume of hydrolyzate (μl) in a test tube at a ratio of 1:3, boil in a boiling water bath for 20 min, and cool in running water.

[0103] The glycogen hydrolyzate was further prepared into a glycogen detection solution: the liver glycogen detection solution was 1%, and the amount of double distilled water added was: liver weight × 100 - liver weight × 4* = liver weight × 96. Note: 4* is the volume of the alkali solution and tissue during hydrolysis.

[0104] Prepare 1% glycogen detection solution, add double distilled water in the amount of: 75×96=7200μl=7.2ml; according to the instructions and Table 5 below, add blank tubes, standard tubes and test tubes respectively.

[0105] After mixing, boil in boiling water for 5 minutes. After cooling, adjust the blank tube to zero and measure the OD value of each tube with an enzyme marker at a wavelength of 620nm and a light path of 1cm.

[0106] Table 5

[0107]

[0108]

[0109] The liver glycogen content was obtained according to the calculation formula:

[0110]

[0111] In the above formula, 0.01mg: standard tube content; 100: refers to the dilution multiple of the sample before testing, that is, the dilution multiple of the sample before testing is 100 in the sample pretreatment step ③; 10: is the dilution multiple during the test; 1.11: is the coefficient for converting the glucose content measured by this method into glycogen content, that is, the color developed by anthrone reagent for 100ug glycogen is equivalent to the color developed by anthrone reagent for 111ug glucose.

[0112] Data processing and result determination: The data were analyzed for significance. If the glycogen content in the test sample group was significantly higher than that in the control group, and the difference was significant (p ≤ 0.05), the experimental result could be determined to be positive.

[0113] C. Blood urea nitrogen test

[0114] One hour after the last administration of the drug to the mice, the mice were placed in 25°C water and swam without load for 90 minutes. They rested for 30 minutes, then their eyeballs were removed to collect blood, which was added to a sodium heparin centrifuge tube and centrifuged at 1500 r / min for 30 minutes. The serum was collected and the urea content was determined using a urea nitrogen kit.

[0115] According to the instructions, add blank tubes, standard tubes and assay tubes according to Table 6 below.

[0116] Mix well, place in boiling water for 15 minutes, and immediately cool with tap water. Measure the OD value of each tube with a microplate reader at a wavelength of 520 nm, a light path of 1 cm, and zero with double distilled water.

[0117] Table 6 Blood urea nitrogen test kit tube grouping

[0118] Reagents Blank tube Standard tube Determination tube Double distilled water (ml) 0.02 -- -- 10mmol / L standard solution (ml) -- 0.02 -- Sample to be tested (ml) -- -- 0.02 Reagent 1 (ml) 1 1 1 Reagent 2 application solution (ml) 1 1 1

[0119] The urea nitrogen content is obtained according to the calculation formula:

[0120]

[0121] In the formula, 10mmol / L: standard concentration; 1: sample dilution multiple before testing; Note: 10mmol / L urea nitrogen = 280.1mg / L; Reference range: Urea concentration range in normal human serum: 2.9~8.2mmol / L.

[0122] Data processing and result determination: The data were analyzed for significance. If the serum urea of ​​the test sample group was lower than that of the control group and the difference was significant (p≤0.05), the experimental result could be determined to be positive.

[0123] D. Blood lactate determination experiment

[0124] Blood was collected 1 hour after the last smoking exposure to the mice. The mice were then placed in 25°C water and allowed to swim without load for 90 minutes. The mice were rested for 30 minutes, and their eyeballs were removed to collect blood. The blood was added to a sodium heparin centrifuge tube and centrifuged at 1500 r / min for 30 minutes. The serum was taken and the lactic acid content was determined using a lactic acid kit.

[0125] Prepare the following solutions according to the instructions:

[0126] Preparation of enzyme working solution: Mix reagent 2 (enzyme stock solution) and reagent 1 (enzyme diluent) at a volume ratio of 1:100 before use. Prepare immediately before use and store at 4°C for 24 hours.

[0127] Preparation of color developer: Before use, take one tube of Reagent 4 powder and pour it into a bottle of Reagent 3 liquid. After the powder is completely dissolved, use a micropipette to take a small amount of liquid into a small centrifuge tube. Invert the centrifuge tube repeatedly, and then use a micropipette to transfer the liquid in the centrifuge tube to the bottle. Repeat this 2 to 3 times to fully mix the two to make a color developer. Store in a refrigerator at 4℃ to 8℃ away from light.

[0128] Preparation of supernatant: Take 0.1 ml of the sample to be tested, add 0.6 ml of protein precipitant and mix well, centrifuge at 3500-4000 rpm for 10 minutes, and take the supernatant for measurement.

[0129] According to the instructions and Table 7 below, add blank tubes, standard tubes and assay tubes respectively.

[0130] Mix well, adjust to zero with double distilled water at 530 nm and 1 cm optical path, and measure the absorbance of each tube with an enzyme-labeled instrument.

[0131] Table 7 Blood lactate test kit tube grouping

[0132]

[0133] The serum lactate content was obtained according to the calculation formula:

[0134]

[0135] In the formula, 3mmol / L: standard concentration; 1: sample dilution multiple before testing.

[0136] Data processing and result determination: Perform a significance analysis on the data. If the blood lactate value of the test sample group is lower than that of the control group and the difference is significant (p≤0.05), the experimental result can be determined to be positive.

[0137] 4-4 Result determination

[0138] If the result of the weighted swimming test is positive, and any two of the three biochemical indicators of blood lactate, serum urea, and liver glycogen are positive, it can be determined that the test sample has the function of relieving physical fatigue.

[0139] 4-5 Results and Conclusions

[0140] The test results can be seen in Table 8.

[0141] Table 8

[0142]

[0143] Note: * indicates that p<0.05 is compared between each example group and the control group; ** indicates that p<0.01 is compared between each example group and the control group; *** indicates that p<0.001 is compared between each example group and the control group.

[0144] According to the criteria for each indicator and the test result data in Table 5, the positive and negative determination of each indicator is as shown in Table 9:

[0145] Table 9

[0146]

[0147] Note: √ indicates that the test sample has the function of relieving physical fatigue; X indicates that the test sample does not have the function of relieving physical fatigue.

[0148] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.

[0149] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. An anti-fatigue pharmaceutical composition that can be atomized and inhaled, characterized in that: include: Active extract and solvent, the components and mass contents of the anti-fatigue pharmaceutical composition that can be atomized and inhaled are: or, The components and mass contents of the anti-fatigue pharmaceutical composition that can be atomized and inhaled are as follows: Or, The components and mass contents of the anti-fatigue pharmaceutical composition that can be atomized and inhaled are as follows: The anti-fatigue pharmaceutical composition capable of being atomized and inhaled is atomized and used through an electronic atomizer.

2. The anti-fatigue pharmaceutical composition capable of being atomized and inhaled according to claim 1, characterized in that: The Herba Lysimachiae extract is prepared by the following method: Weigh 1 kg of Herba Cynoglossi tablets, use 75-95% ethanol in an amount 8-15 times the mass of the Herba Cynoglossi tablets for ultrasonic extraction for 30-120 minutes, filter to obtain a primary filtrate and a filter residue, add the 75-95% ethanol in an amount 3-8 times the mass of the Herba Cynoglossi tablets to the filter residue, ultrasonically extract for 10-60 minutes, filter to obtain a secondary filtrate, combine the primary filtrate and the secondary filtrate, and concentrate under reduced pressure to 300-500 g to obtain a concentrated solution; then add 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitate with alcohol for at least 10 hours, and take the supernatant; concentrate the supernatant under reduced pressure to dryness, then dissolve it with a small amount of 0-30% ethanol, pass it through a macroporous resin, elute it with the 75-95% ethanol, and collect the eluate; concentrate the eluate under reduced pressure, and then freeze-dry or vacuum-dry it to make powder to obtain the Herba Cynoglossi extract.

3. The anti-fatigue pharmaceutical composition capable of being atomized and inhaled according to claim 1, characterized in that: The kudzu root extract is prepared by the following method: 1 kg of kudzu root block is weighed, 75-95% ethanol in an amount of 8-15 times the mass of the kudzu root block is used for ultrasonic extraction for 30-120 minutes, and a primary filtrate and a filter residue are obtained by filtering. The 75-95% ethanol in an amount of 3-8 times the mass of the kudzu root block is added to the filter residue, and ultrasonic extraction is performed for 10-60 minutes, and a secondary filtrate is obtained by filtering. The primary filtrate and the secondary filtrate are combined, and the filtrate is concentrated under reduced pressure to 300-500 g to obtain a concentrated solution; then 3-5 kg ​​of 95% ethanol aqueous solution is added to the concentrated solution while stirring, and the solution is precipitated with alcohol for at least 10 hours to obtain a supernatant; the supernatant is concentrated to dryness, and then dissolved with a small amount of 0-30% ethanol, passed through a macroporous resin, and eluted with 20-40% ethanol and the 75-95% ethanol in sequence, and the eluates are collected respectively, and the eluate eluted with the 75-95% ethanol is concentrated under reduced pressure and then powdered by freeze drying or vacuum drying to obtain the kudzu root extract.

4. The anti-fatigue pharmaceutical composition capable of being atomized and inhaled according to claim 1, characterized in that: The polygonatum odoratum extract, the ginseng extract, and the American ginseng extract are prepared by the following methods: Weigh 1 kg of active raw material, which is Polygonatum odoratum slices, ginseng or American ginseng, use 65-85% ethanol in an amount of 8-15 times the mass of the active raw material for ultrasonic extraction for 30-120 minutes, filter to obtain a primary filtrate and a filter residue, add 65-85% ethanol in an amount of 3-8 times the mass of the active raw material to the filter residue, ultrasonically extract for 10-60 minutes, filter to obtain a secondary filtrate, combine the primary filtrate and the secondary filtrate, and concentrate under reduced pressure to 500-800 g to obtain a concentrated solution; then add 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitate with alcohol for at least 10 hours, and take the supernatant; reduce the pressure and concentrate the supernatant until there is no alcohol taste, and then freeze-dry or vacuum-dry to powder to obtain the active extract.

5. The anti-fatigue pharmaceutical composition capable of being atomized and inhaled according to claim 1, characterized in that: The dried ginger extract is prepared by the following method: Weigh 1 kg of an active raw material, which is dried ginger, use 50-70% ethanol in an amount of 8-15 times the mass of the active raw material for ultrasonic extraction for 30-120 minutes, filter to obtain a primary filtrate and a filter residue, add 50-70% ethanol in an amount of 3-8 times the mass of the active raw material to the filter residue, ultrasonically extract for 10-60 minutes, filter to obtain a secondary filtrate, combine the primary filtrate and the secondary filtrate, and concentrate under reduced pressure to 300-500 g to obtain a concentrated solution; then add 3-5 kg ​​of an aqueous solution of 95% ethanol to the concentrated solution while stirring, precipitate with alcohol for at least 10 hours, and take a supernatant; reduce the pressure on the supernatant to concentrate until there is no alcohol taste, and then freeze-dry or vacuum-dry to powder to obtain the active extract.

6. The anti-fatigue pharmaceutical composition capable of being atomized and inhaled according to claim 1, characterized in that: The Cordyceps sinensis extract is prepared by the following method: Weigh 1 kg of Cordyceps sinensis, use 65-85% ethanol in an amount 20-40 times the mass of the Cordyceps sinensis for ultrasonic extraction for 30-120 minutes, filter to obtain a primary filtrate and a filter residue, add the 65-85% ethanol in an amount 10-20 times the mass of the Cordyceps sinensis to the filter residue, ultrasonically extract for 10-60 minutes, filter to obtain a secondary filtrate, combine the primary filtrate and the secondary filtrate, and concentrate under reduced pressure to 500-800 g to obtain a concentrated solution; then add 3-5 kg ​​of 95% ethanol aqueous solution to the concentrated solution while stirring, precipitate with alcohol for at least 10 hours, and take the supernatant; reduce the pressure and concentrate the supernatant until there is no alcohol taste, and then freeze-dry or vacuum-dry to powder to obtain the Cordyceps sinensis extract.

Images